Success Metrics

Active Trials
6(100%)

Phase Distribution

Ph phase_3
4
67%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 3Large-scale testing
4(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

6

all time

Status Distribution
Active(6)

Detailed Status

Recruiting5
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
6
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 34 (66.7%)

Trials by Status

recruiting583%
active_not_recruiting117%

Recent Activity

6 active trials
Showing 5 of 6
recruitingphase_3

A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07701993
recruitingphase_3

A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07704892
recruitingphase_3

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

NCT07221188
recruitingphase_3

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

NCT07221227
active_not_recruitingphase_1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry

NCT07335198
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07701993Phase 3

A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

Recruiting
NCT07704892Phase 3

A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

Recruiting
NCT07221188Phase 3

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Recruiting
NCT07221227Phase 3

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Recruiting
NCT07335198Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry

Active Not Recruiting
NCT07358546Phase 1

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6